2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153660S
    Bivamelagon-d8
    Bivamelagon-d8 (MC-4R Agonist 2-d8) is the deuterium labeled Bivamelagon (HY-153660). Bivamelagon (MC-4R Agonist 2) is an orally active MC4R agonist with EC50 values of 0.562 nM (Luci assay) and 36.5 nM (cAMP assay), and a Ki of 65 nM. Bivamelagon can be used for the research of diseases such as obesity and diabetes.
    Bivamelagon-d8
  • HY-153830S
    LacCer (d18:1/16:0)-d3 2097249-92-6 98%
    LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d3 is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases.
    LacCer (d18:1/16:0)-d3
  • HY-153938A
    PROTAC PTPN2 degrader-2 TFA 2912307-39-0 98%
    PROTAC PTPN2 degrader-2 TFA is a potent PTPN2 PROTAC degrader with a DC50 of <50 nM. PROTAC PTPN2 degrader-2 TFA is potential for studying cancer or metabolic diseases, such as colon cancer.
    PROTAC PTPN2 degrader-2 TFA
  • HY-15398S1
    Vitamin D3-13C3 98%
    Vitamin D3-13C3 is the 13C-labeled Vitamin D3. Vitamin D3 (Cholecalciferol; Colecalciferol) is a naturally occuring form of vitamin D. Vitamin D3 induces cell differentiation and prevents proliferation of cancer cells.
    Vitamin D3-13C3
  • HY-15461S1
    Ertugliflozin-d9 98%
    Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
    Ertugliflozin-d9
  • HY-157189A
    GPR132 antagonist 1 (dihydrocholide) 98%
    GPR132 antagonist 1 dihydrocholide (GPR132-B-160, Compound 25) is a GPR132 antagonist with an EC50 value of 0.075 μM. GPR132 antagonist 1 dihydrocholide has promote insulin secretion activity with an EC50 value of 0.7 μM.
    GPR132 antagonist 1 (dihydrocholide)
  • HY-157502S
    Buctopamine-d9 98%
    Buctopamine-d9 is the deuterium labeled Buctopamine. Buctopamine is a β2 adrenoceptor agonist.
    Buctopamine-d9
  • HY-157541S
    2-Chloro-1,3-propanediol-13C3 2813343-29-0
    2-Chloro-1,3-propanediol-13C3 is the 13C-labeled 2-Chloro-1,3-propanediol. 2-Chloro-1,3-propanediol is an ester product.
    2-Chloro-1,3-propanediol-13C3
  • HY-158362A
    Monoglyceride lipase, Bacillus sp. 9040-75-9 98%
    Monoglyceride lipase, Bacillus sp., is a key enzyme involved in lipid metabolism. It catalyzes the hydrolysis of monoglycerides (particularly 2-AG, or 2-arachidonoylglycerol) into glycerol and free fatty acids. By regulating the levels of 2-AG, Monoglyceride lipase, Bacillus sp., can influence neural signaling, pain perception, inflammatory responses, and metabolic processes.
    Monoglyceride lipase, Bacillus sp.
  • HY-159642G
    Dabogratinib (GMP) 2800223-30-5 98%
    Dabogratinib (TYRA-300) (GMP) is Dabogratinib (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Dabogratinib is an orally active, selective FGFR3 inhibitor with an IC50 of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia.
    Dabogratinib (GMP)
  • HY-159691B
    IONIS-FGFR4Rx sodium scrambled negative control 98%
    IONIS-FGFR4Rx sodium scrambled negative control is the sequence scrambled negative control of IONIS-FGFR4Rx sodium.
    IONIS-FGFR4Rx sodium scrambled negative control
  • HY-159691C
    FAM labled IONIS-FGFR4Rx sodium 98%
    FAM labled IONIS-FGFR4Rx sodiumis a FAM labled IONIS-FGFR4Rx sodium.
    FAM labled IONIS-FGFR4Rx sodium
  • HY-159691D
    Cy3 labled IONIS-FGFR4Rx sodium 98%
    Cy3 labled IONIS-FGFR4Rx sodium is a Cy3 labled IONIS-FGFR4Rx sodium.
    Cy3 labled IONIS-FGFR4Rx sodium
  • HY-159694A
    IONIS PTP1BRx sodium 98%
    IONIS PTP1BRx (ISIS 404173) sodium is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx sodium shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity.
    IONIS PTP1BRx sodium
  • HY-159694B
    IONIS PTP1BRx sodium scrambled negative control 98%
    IONIS PTP1BRx sodium scrambled negative control is the sequence scrambled negative control of IONIS PTP1BRx sodium.
    IONIS PTP1BRx sodium scrambled negative control
  • HY-159694C
    FAM labled IONIS PTP1BRx sodium 98%
    FAM labled IONIS PTP1BRx sodiumis a FAM labled IONIS PTP1BRx sodium.
    FAM labled IONIS PTP1BRx sodium
  • HY-159694D
    Cy3 labled IONIS PTP1BRx sodium 98%
    Cy3 labled IONIS PTP1BRx sodium is a Cy3 labled IONIS PTP1BRx sodium.
    Cy3 labled IONIS PTP1BRx sodium
  • HY-159696A
    ISIS 449884 sodium 98%
    ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM).
    ISIS 449884 sodium
  • HY-159696B
    ISIS 449884 sodium scrambled negative control 98%
    ISIS 449884 sodium scrambled negative control is the sequence scrambled negative control of ISIS 449884 sodium.
    ISIS 449884 sodium scrambled negative control
  • HY-159696C
    FAM labled ISIS 449884 sodium 98%
    FAM labled ISIS 449884 sodiumis a FAM labled ISIS 449884 sodium.
    FAM labled ISIS 449884 sodium
Cat. No. Product Name / Synonyms Application Reactivity